Claudin18.2-Targeted SPECT/CT Imaging for Gastric Cancer: Preclinical Evaluation and Clinical Translation of the ^99mTc-Labeled Nanobody (PHG102) Radiotracer.

ABSTRACT: Claudin18.2 (CLDN18.2) has emerged as a significant target in the treatment of advanced gastric cancer. The screening of patients positive for CLDN18.2 is crucial for the effective application of targeted therapies specific to CLND18.2. In this study, we developed a novel nanobody-based probe, [^99mTc]Tc-PHG102, for use in nuclear medicine. We analyzed its radiochemical yield and stability to ensure accurate probe characterization. Additionally, we assessed the probe's affinity and specificity toward the CLDN18.2 target and evaluated its efficacy in the BGC823^18.2 xenograft model for SPECT/CT imaging of gastric cancer. The binding of [^99mTc]Tc-PHG102 to HEK-293T^18.2 and BGC823^18.2 cells was notably higher than its binding to HEK-293T

SUBMITTER: Bai Z 

PROVIDER: S-EPMC11320725 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature